Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors
Genes · 25.02.2023 · 14 (3) · 578
DOI: 10.3390/genes14030578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 25.02.2023. Verfasst von Amar D Levens und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Cytochrome P-450 CYP2C19, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Angiocare.
Abstract (Originalsprache)
Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y12-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—particularly in an outpatient setting—remains limited. We conducted a proof-of-concept study to evaluate the feasibility of CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel through point-of-care (POC) PGx testing in the community pharmacy. Multiple feasibility outcomes were assessed. Overall, 144 patients underwent CYP2C19 PGx testing in 27 community pharmacies. Successful test results were obtained in 142 patients (98.6%). De-escalation to clopidogrel occurred in 19 patients (20%) out of 95 (67%) eligible for therapy de-escalation, which was mainly due to PGx testing not being included in cardiology guidelines. Out of the 119 patients (84%) and 14 pharmacists (100%) surveyed, 109 patients (92%) found the community pharmacy a suitable location for PGx testing, and the majority of pharmacists (86%) thought it has added value. Net costs due to PGx testing were estimated at €43 per patient, which could be reduced by earlier testing and could turn into savings if de-escalation would double to 40%. Although the observed de-escalation rate was low, POC CYP2C19-guided de-escalation to clopidogrel appears feasible in a community pharmacy setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
- Department of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
- Netherlands Heart Institute, 3511 EP Utrecht, The Netherlands.
- SIR Institute for Pharmacy Practice and Policy, 2331 JE Leiden, The Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
ORCID-Profile: Amar D Levens, J Wouter Jukema, Mette Heringa, Jesse J Swen
Förderung
- Angiocare
Zitieren
APA
Levens, A. D., den Haan, M. C., Jukema, J. W., Heringa, M., van den Hout, W. B., Moes, D. J. A. R., & Swen, J. J. (2023). Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes, 14(3), 578. https://doi.org/10.3390/genes14030578
Vancouver
Levens AD, den Haan MC, Jukema JW, Heringa M, van den Hout WB, Moes DJAR, et al. Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes. 2023;14(3):578. doi:10.3390/genes14030578
BibTeX
@article{Levens2023,
author = {Levens, Amar D and den Haan, Melina C and Jukema, J Wouter and Heringa, Mette and van den Hout, Wilbert B and Moes, Dirk Jan A R and Swen, Jesse J},
title = {Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors},
journal = {Genes},
year = {2023},
volume = {14},
number = {3},
pages = {578},
doi = {10.3390/genes14030578}
}
EUVIMED